Elranatamab

埃纳妥单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameElranatamab
Drug Alias Nameelranatamab-bcmmElrantamabEnatumabElrexfioELREXFIO +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers
Mechanisms of ActionB-cell maturation protein modulatorsT-cell surface glycoprotein CD3 epsilon chain modulators
TargetsB-cell maturation proteinT-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsAnemia, Hemolytic, AutoimmuneSpinal Cord DiseasesSmoldering Multiple Myeloma +[6] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2023/08/14
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalPeking Union Medical College HospitalPharmacia & Upjohn Company Llc +[9] 
Inactive CompaniesWashington University School Of MedicinePfizer Manufacturing Belgium NvUniversity Of California San Diego
Active IndicationsAnemia, Hemolytic, AutoimmuneSpinal Cord DiseasesSmoldering Multiple Myeloma +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG